心動過緩治療 - Pindolol

Management of bradycardia depends on the severity of symptoms, as bradycardia is usually not a dangerous condition and does not require treatment. Bradycardia that does not cause symptoms such as dizziness, weakness, or fainting is usually not treated.

Factors that influence whether any treatment plan is used in cases of bradycardia include:

  • severity of symptoms
  • Correlation between bradycardia and its symptoms
  • Have a serious underlying medical condition, such as heart block
  • There is a potentially reversible cause that can be treated

treatment outline

Listed below are some examples of the types of treatments that can be used to treat bradycardia.

  • In cases of bradycardia caused by drugs that slow the heartbeat, the drug is usually discontinued.
  • For example, in cases of bradycardia caused by low or high potassium levels, electrolyte imbalances may need to be corrected.
  • A pacemaker may be implanted to regulate the heart's rhythm. Pacemakers are tiny devices that generate electrical pulses if they detect an abnormality in the pulses produced by the heart's sinoatrial node. A pacemaker is implanted under the skin and permanently attached to the heart. When they detect a slow or abnormal heart rhythm, they send impulses to correct the heart rate.

According to the guidelines of the American College of Cardiology and the American Heart Association, pacemaker implantation is only performed under certain conditions. These include:

  • Third-degree heart block (or atrioventricular block) occurs when the patient's heartbeat is missing for 3 seconds or more or when the patient's heart rate is less than 40 bpm while awake.
  • Third degree heart block or second degree Mobitz type heart block combined with chronic bifascicular and trifascicular block.
  • Congenital third-degree heart block with a wide QRS escape rhythm (as shown on the electrocardiogram), ventricular dysfunction (disordered ventricular pumping), or age-inappropriate bradycardia.

Less commonly accepted indications for pacemaker use in bradycardia are known as Class II recommendations. These include:

  • In third-degree heart block, the escape rate is faster in awake patients and there are no obvious symptoms.
  • Second-degree Mobitz type heart block in patients without bifascicular or trifascicular block.
  • There is a block under or within the His bundle

When the bradycardia occurs only during sleep, even if the bradycardia is severe, the use of a pacemaker is usually not recommended. These patients may benefit from pindolol, a beta-blocker with intrinsic sympathomimetic activity.

Patients with impending heart failure or unstable bradycardia require immediate treatment. The drug of choice is usually atropine 0.5-1.0 mg administered intravenously at intervals of 3 to 5 minutes, with a maximum dose of 0.04 mg/kg. Other emergency medications that may be given include adrenaline and dopamine.

Pindolol

Pindolol, sold under the brand name Visken and others, is a non-selective beta blocker used to treat high blood pressure. It is also an antagonist of serotonin 5-HT 1A receptors, preferentially blocking inhibitory 5-HT 1A autoreceptors, and has been studied as an add-on therapy to selective serotonin reuptake inhibitors (SSRIs) for the treatment of depression disease.

medical use

It is used to treat high blood pressure in the United States, Canada, and Europe, and also to treat angina pectoris outside the United States. When used alone in high blood pressure, it can significantly reduce blood pressure and heart rate, but the evidence base for its use is weak due to the small number of participants in published studies. In some countries, Pindolol is also used for the prevention of cardiac arrhythmias and acute stress reactions.

Contraindications

Contraindicated in hyperthyroidism. The possible harmful effects of long-term use of Pindolol have not been fully evaluated in patients with thyrotoxicosis. Beta-blockers may mask clinical signs of persistent hyperthyroidism or complications and give a false impression of improvement. Therefore, sudden discontinuation of Pindolol may worsen the symptoms of hyperthyroidism, including thyroid storm. Pindolol has intrinsic sympathomimetic activity and should be used with caution in angina.

pharmacodynamics

Pindolol is a first-generation non-selective beta-blocker in the beta-adrenergic receptor antagonist class. At the receptor level, it is a competitive partial agonist. It has intrinsic sympathomimetic activity, meaning that it has some degree of agonist action in the absence of competing ligands. Pindolol shows membrane stabilizing effects like quinidine, which may be responsible for its antiarrhythmic effects. It also acts as a partial agonist (intrinsic activity = 20–25%) or functional antagonist of the serotonin 5-HT 1A receptor

Pindolol is rapidly and well absorbed in the gastrointestinal tract. It undergoes some first-pass metabolism, resulting in an oral bioavailability of 50-95%. Bioavailability may be reduced in uremic patients. Food does not alter bioavailability but may increase absorption. Peak plasma concentrations are reached within 1-2 hours after a single oral dose of 20 mg. The effect of Pindolol on pulse rate (reduction) is evident after 3 hours. Although the half-life of 3-4 hours is rather short, the hemodynamic effects persist for 24 hours after administration. The plasma half-life increases to 3-11.5 hours in patients with renal insufficiency, to 7-15 hours in elderly patients, and from 2.5 hours to 30 hours in patients with cirrhosis. Approximately two-thirds of pindolol is metabolized in the liver to produce hydroxylates, which are present in the urine as glucouridine and ether sulfate. The remaining 1/3 of pindolol is excreted unchanged in the urine.

history

Pindolol was patented by Sandoz in 1969 and launched in the United States in 1977. In February 2020, the FDA added the product to its "drug shortage" list, noting that it was due to a "shortage of active ingredients" that was potentially related to the coronavirus outbreak and related supply chain impacts.

Review

All comments are moderated before being published

HealthyPIG Magazine

View all
用粟粉醃肉有乜科學根據?揭開中菜「滑肉」嘅秘密

用粟粉醃肉有乜科學根據?揭開中菜「滑肉」嘅秘密

前言:點解中餐炒肉咁滑? 好多香港人炒肉嘅時候都會發現,餐廳啲雞絲牛柳炒出嚟特別滑溜、唔鞋口。呢個秘密,唔喺高級食材,而係一個平凡但強大嘅材料——粟粉(Cornstarch)。 呢種技巧叫做**「走油前醃」或「滑油醃肉法」(Velveting)**,係中餐獨有技術之一,主要靠粟粉、蛋白、調味料...
咩係三價鐵(Fe³⁺)同二價鐵(Fe²⁺)?

咩係三價鐵(Fe³⁺)同二價鐵(Fe²⁺)?

當我哋講「鐵質」時,唔止係話有冇攝取足夠,而係講緊鐵喺人體內唔同形態(尤其係三價鐵 Fe³⁺ 同二價鐵 Fe²⁺)點樣被吸收、轉化、運輸同儲存,呢啲都深深影響生物可利用率

全面解構低鐵原因、病理機制及影響

全面解構低鐵原因、病理機制及影響

低鐵唔止係營養問題,仲可能係身體慢性警號

鐵質(iron)係人體不可或缺嘅微量元素,主要負責攜帶氧氣嘅血紅素(hemoglobin)製造、能量代謝、免疫調節等。當鐵質長期攝取不足、吸收差、或失去過多,就會導致「低鐵」(iron deficiency)甚至發展成「缺鐵性貧血」(iron deficiency anemia)。本文將從臨床醫學與分子生理角度,深入探討低鐵嘅成因、病理機制、生物轉化過程,以及其對人體造成嘅連鎖影響。

Obefazimod(ABX464):潰瘍性結腸炎新藥研究、作用機制與研發進展

Obefazimod(ABX464):潰瘍性結腸炎新藥研究、作用機制與研發進展

Obefazimod(又名 ABX464)係由法國生物科技公司 Abivax 開發嘅口服小分子創新藥,目標治療慢性發炎性腸道疾病(IBD),特別係潰瘍性結腸炎(UC)同克羅恩氏病(CD)患者。

夢遺係唔係一定關性事?

夢遺係唔係一定關性事?

夢遺,即係在無意識之下於睡眠中射精,係一種常見於青春期男生甚至成年男性身上的自然生理現象。夢遺唔等於一定發生性夢,也唔等於有性慾過強。它與睡眠週期中快速動眼期(REM sleep)嘅勃起模式有關,亦可能反映正常的荷爾蒙波動及精液排出節律。 咩係夢遺? 夢遺(nocturnal emission...
唔凍都會打冷震?

唔凍都會打冷震?

打冷震(shivering)唔一定因為天氣凍,喺情緒波動、發燒初期、焦慮、緊張等情況下都可以出現。打冷震係一種由大腦下視丘控制嘅「非意識性肌肉收縮」,目的係維持或調節核心體溫或應對突發壓力。了解打冷震背後嘅神經與體溫調節原理,可以幫我哋區分「正常生理反應」同「潛在疾病警號」。 打冷震係乜回事...
一緊張就流手汗?

一緊張就流手汗?

手掌汗腺主要受交感神經系統控制。當人面對壓力、驚訝、社交場合等刺激時,大腦會啟動「戰鬥或逃跑反應」,促使手掌、腳底等部位產生明顯出汗。這種情況屬於精神性出汗,與溫度無直接關係,係身體對外在壓力的自然反應。

起身「眼前一黑」係咩事?

起身「眼前一黑」係咩事?

當你由坐或瞓姿突然企起,血液未能即時供應足夠氧氣到腦部,形成姿勢性低血壓(orthostatic hypotension),導致短暫性視野模糊、頭暈甚至站立不穩。青少年、長者、飲水不足或患有自律神經功能障礙人士較常出現。

瞓覺點解會流口水?

瞓覺點解會流口水?

唾液分泌受副交感神經控制,當身體進入深層睡眠並肌肉放鬆時,容易出現流口水現象,尤其側睡或口微開者更明顯。